A decision-analytic model was used to estimate cost-effectiveness of adopting a 21-gene assay in treatment decisions for women with early-stage N (1-3)/ER HER2-negative breast cancer.
Michael S. Broder, MD
Advertisement
Articles by Michael S. Broder, MD
The ratio of controller to total asthma medications can be calculated using 1 or 2 quarters of data; high versus low ratios differentiate patient characteristics.
Advertisement
Latest Updated Articles
- Cost-Effectiveness of 21-Gene Assay in Node-Positive, Early-Stage Breast Cancer
Published: July 12th 2011 | Updated:
- Ratio of Controller to Total Asthma Medications: Determinants of the Measure
Published: March 9th 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5
